Display options
Cite
Atmar J. Review of the safety and feasibility of rapid infusion of rituximab. J Oncol Pract. 2010;6(2):91-3doi: 10.1200/JOP.200001.
Atmar, J. (2010). Review of the safety and feasibility of rapid infusion of rituximab. Journal of oncology practice, 6(2), 91-3. https://doi.org/10.1200/JOP.200001
Atmar, Jill. "Review of the safety and feasibility of rapid infusion of rituximab." Journal of oncology practice vol. 6,2 (2010): 91-3. doi: https://doi.org/10.1200/JOP.200001
Atmar J. Review of the safety and feasibility of rapid infusion of rituximab. J Oncol Pract. 2010 Mar;6(2):91-3. doi: 10.1200/JOP.200001. PMID: 20592783; PMCID: PMC2835489.
Copy Download .nbib Format: NLM
Share it on

J Oncol Pract. 2010 Mar;6(2):91-3. doi: 10.1200/JOP.200001.

Review of the safety and feasibility of rapid infusion of rituximab.

Journal of oncology practice

Jill Atmar

Affiliations

  1. Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

PMID: 20592783 PMCID: PMC2835489 DOI: 10.1200/JOP.200001

Abstract

Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.

References

  1. Ann Oncol. 2006 Jun;17(6):1027-8 - PubMed
  2. J Clin Oncol. 2001 Apr 15;19(8):2153-64 - PubMed
  3. Blood. 2007 May 15;109(10):4171-3 - PubMed
  4. Annu Rev Med. 2004;55:477-503 - PubMed
  5. Annu Rev Med. 2008;59:237-50 - PubMed
  6. Lancet Oncol. 2006 May;7(5):379-91 - PubMed
  7. Blood. 2005 Feb 15;105(4):1417-23 - PubMed
  8. Eur J Haematol. 2006 Oct;77(4):338-40 - PubMed
  9. Clin Cancer Res. 2008 Dec 1;14(23):7935-9 - PubMed
  10. Eur J Haematol. 2009 Apr;82(4):322-5 - PubMed
  11. J Oncol Pharm Pract. 2009 Sep;15(3):183-6 - PubMed
  12. Oncologist. 2008 Jun;13(6):725-32 - PubMed
  13. N Engl J Med. 2002 Jan 24;346(4):235-42 - PubMed

Publication Types